Mutations in the EGFR gene, such as the EGFRvIII variant, lead to constant receptor activation and downstream signaling through the phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) pathway, promoting tumor growth and therapy resistance [11]. Here, MTOR is linked to neoplasm.